Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

The first effective and safe reversal agent to stop or prevent life-threatening bleeding in patients taking the emerging generation of anticoagulants.

Obiettivo

50 Million patients worldwide use oral anticoagulants to prevent venous thrombosis and stroke. Since the last decade, unpredictable and risky indirect anticoagulant treatments are being replaced by the latest generation of blood-thinning medication: Factor Xa Direct Oral Anticoagulants (FXa-DOACs, used by >10 million patients in EU+US). With superior predictability, efficacy and safety profiles, these life-saving medications remain associated with a risk of uncontrolled and severe bleeding. Alarmingly, there is no safe reversal agent that restores blood clotting in patients who take FXa-DOACs, resulting in life-threatening bleeding episodes and >400k hospital admissions. To address the urgent unmet need, VarmX has developed VMX-C001, the first effective and safe reversal agent to FXa-DOACs. VarmX requests a €2,5M in grant and €15M in equity EIC to accelerate upscaling and improve the cost-effectiveness of the complex manufacturing process required to produce VMX-C001.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2021-ACCELERATOROPEN-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

VARMX BV
Contributo netto dell'UE
€ 2 500 000,00
Indirizzo
MIDDELWEG 38B
2312 KJ Leiden
Paesi Bassi
PMI
Sì
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 4 842 087,50